Applications are now being accepted for the West Coast session of ASCO’s Quality Training Program, which will be held off-site near City of Hope in California, beginning in January. Applications are due Friday, December 7, 2018.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA®, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.
President Trump recently signed a pair of bills into law aimed at increasing transparency with regard to drug prices in the United States. The Patient Right to Know Drug Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553) prohibit so-called "gag clauses," which prevent pharmacists from telling customers if they could save money by buying prescription drugs out-of-pocket rather than using their health insurance. S. 2554 applies to private health plans, while S. 2553 targets Medicare Part D and Medicare Advantage plans.
Clifford A. Hudis, MD, FACP, FASCO, CEO of ASCO and Robert S. Miller, MD, FACP, FASCO, Medical Director of CancerLinQ LLC, will be speaking at the upcoming Association for Value-Based Cancer Care 2018 Summit in New York, NY from October 30-31, 2018.
As Hurricane Michael poses a threat to Florida and other states, ASCO has assembled a list of resources and information to support cancer care providers and patients.
In the latest ASCO in Action Podcast, Dr. Ray Page, DO, PhD, FACOI joins ASCO CEO Dr. Clifford A. Hudis to discuss the impact that Pharmacy Benefit Managers (PBMs) are having on cancer care delivery and ASCO’s recent position statement on PBMs.
On October 4, 2018, the Food and Drug Administration approved emicizumab-kxwh injection (HEMLIBRA®, Genentech, Inc.) for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.
ASCO is assembling a cohort of its members who are willing to participate in survey-based research projects of ASCO members for non-commercial purposes. The immense knowledge and experience of ASCO’s membership can help to accelerate the development of new insights and findings that may help to improve care and care delivery.
The Center for Medicare & Medicaid Services (CMS) has released performance feedback for Merit-based Incentive Payment System (MIPS) clinicians who participated the 2017 performance year. Individual clinicians, groups, and eligible clinicians in certain Alternative Payment Models (APMs) can access a comprehensive overview of their MIPS final score, performance category details, and 2019 MIPS payment adjustment on the Quality Payment Program (QPP) website.
The Centers for Medicare & Medicaid Services (CMS) and its contractor, Acumen LLC, are field testing 13 cost measures before consideration of their potential use in the cost performance category of the Merit-based Incentive Payment System (MIPS) under the Quality Payment Program in 2020 or beyond.
On September 28, 2018, the Food and Drug Administration approved cemiplimab-rwlc (LIBTAYO®, Regeneron Pharmaceuticals Inc.) for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 159 physician investigators and research staff from 34 states across the country—its largest meeting to-date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The meeting, held annually at ASCO's headquarters in the Washington DC Metro area, spanned two days from September 23-24, with a theme of Innovative Solutions. Best Practices. Excellence in Cancer Research.
In a comment letter from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the Food and Drug Administration (FDA) Commissioner Scott Gottlieb, the society expressed appreciation for FDA’s efforts to gather stakeholder perspectives on enhancing access to biologic cancer therapies and ensuring greater availability of biosimilars, while retaining a balance between innovation and competition.
On September 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
More than 100 ASCO volunteers from across the country came to Capitol Hill on September 25-26 for the 2018 ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to support cancer research and ensure access to high-quality care for the millions of people in the United States with cancer.